Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-03
2005-05-03
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S051000, C514S912000, C514S915000
Reexamination Certificate
active
06887858
ABSTRACT:
A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate [UTP], dinucleotides, cytidine 5′-triphosphate [CTP], adenosine 5′-triphosphate [ATP], or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.
REFERENCES:
patent: 4380239 (1983-04-01), Crawford
patent: 4658816 (1987-04-01), Ector, Jr.
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 4868154 (1989-09-01), Gilbard et al.
patent: 4921485 (1990-05-01), Griffiths
patent: 5021043 (1991-06-01), Becker
patent: 5062831 (1991-11-01), Griffiths
patent: 5169386 (1992-12-01), Becker
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5345948 (1994-09-01), O'Donnell, Jr.
patent: 5789391 (1998-08-01), Jacobus et al.
patent: WO 97 35591 (1997-10-01), None
patent: WO 98 03177 (1998-01-01), None
patent: WO 98 03182 (1998-01-01), None
patent: WO 98 03182 (1998-01-01), None
Al-Hussein, H., et al., “Silastic Intubation in Congenital Nasolacrimal Duct Obstruction: A Study of 129 Eyes”Ophthalmic Plastic&Reconstructive Surgery9(1):32-37 (1993).
Bartley, G.B., “Acquired Lacrimal Drainage Obstruction: An Etiologic Classification System, Case Reports, and a Review of the Literature. Part 1”Ophthalmic Plastic Reconstructive Surgery, 8(4):237-242 (1992).
Blicker, J.A., et al., “Lacrimal Sac, Conjunctival, and Nasal Culture Results in Dacryocystorhinostomy Patients,”Ophthalmic Plastic&Reconstructive Surgery, 9(1):43-46 (1993).
Conway, S.T., “Evaluation and Management of “Functional” Nasolacrimal Blockage: Results of a Survey of the American Society of Ophthalmic Plastic and Reconstructive Surgery,”Ophthalmic Plastic&Reconstructive Surgery, 10(3):185-188 (1994).
Dortzbach, R.K., et al., “Silicone Intubation for Obstruction of the Nasolacrimal Duct in Children,”American Journal of Ophthalmology. 94(5):585-590 (1982).
Foster, J.A., et al., “Results of Dacryoscintigraphy in Massage of the Congenitally Blocked Nasolacrimal Duct,”Ophthalmic Plastic and Reconstructive Surgery12(1):32-37 (1996).
Hyde, K.J., et al., “Epidemic Keratoconjunctivitis and Lacrimal Excretory System Obstruction,”Opthamol., 95(10):1447-1449 (1988).
Kassoff, Jr., et al., “Early office-based vs late hospital-based nasolacrimal duct probing. A clinical decision analysis”Arch. Opthalmol113(9):1168-1171 (1995).
Linberg, J.V., et al., “Primary Acquired Nasolacrimal Duct Obstruction A Clinicopathogenic Report and Biopsy Technique,”Opthalmol., 93(8):1055-1063 (1986).
Mauriello, Jr., J.A., et al., “Clinicopathogenic Study of Lacrimal Sac and Nasal Mucosa in 44 Patients with Complete Acquired Nasolacrimal Duct Obstruction,”Opthalmic Plastic&Reconstructive Surgery, 8(1):13-21 (1992).
Shermetaro, C., et al., “Adult nasolacrimal duct obstruction,”JAOA94(3):229-232 (1994).
Tarbet, K.J., et al., “External Dacryocystorhinostomy Surgical Success, Patient Satisfaction, and Economic Cost”,Opthalmol., 102(7):1065-1070 (1995).
Young, J.D.H., et al., “Congenital nasolacrimal duct obstruction in the second year of life: a multicentre trial of management,”Eye, 10:485-491 (1996).
Jacobus Karla M.
Pendergast William
Rideout Janet L.
Yerxa Benjamin R.
Halluin Albert P.
Howrey Simon Arnold & White , LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Owens, Jr. Howard V
LandOfFree
Method of treating dry eye disease with purinergic receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating dry eye disease with purinergic receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating dry eye disease with purinergic receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3439227